About 6.7 million Americans live with heart failure. When the heart pumps weakly (reduced ejection fraction), four drug classes together lower death and hospital stays: ARNI or ACE/ARB, beta-blockers, MRAs and SGLT2 inhibitors. When pumping is preserved (HFpEF), SGLT2 inhibitors and now finerenone help, and weight-loss drugs help people with obesity. Research is targeting aldosterone, inflammation and obesity, testing long-acting injections, and repairing leaky valves with catheters.
- 1,485studies open or running
- 77phase 3 trials
- 7,337papers published this year
- 40NIH-funded projects
-
Now
Nov 2026
New drugs for preserved pumpingHappened 9.9% death or worsening HF
Finerenone cut worsening heart failure events (842 vs 1,024); tirzepatide lowered death or worsening heart failure in obesity (9.9% vs 15.3%).
9.9%: had cardiovascular death or worsening heart failure, vs 15.3% with placebo.
Old drugs, new evidenceHappened 39.5% died or hospitalized
Digitoxin lowered death or hospitalization (39.5% vs 44.1%); IV iron gave a modest benefit; strict fluid limits did not improve wellbeing.
39.5%: died or were hospitalized for heart failure, vs 44.1% with placebo.
Fixing leaky tricuspid valvesHappened 52.4% event-free at 3 years
Catheter repair kept 52.4% free of death or heart failure hospitalization at 3 years vs 21.0%.
52.4%: free of death or heart failure hospitalization at 3 years, vs 21.0%.
-
6 months
by May 2027
Calming inflammationLikely
Novo Nordisk's ATHENA (673 people) tests ziltivekimab, an IL-6 antibody, on symptoms and function in HFpEF with inflammation; due October 2026.
A new MRA combined with dapagliflozinPossible
AstraZeneca's BalanceD-HF (3,850 people) tests balcinrenone plus dapagliflozin in heart failure with kidney impairment; due April 2027.
-
12 months
by Nov 2027
Finerenone in hospital and with SGLT2 drugsPossible 842 worsening HF events
REDEFINE-HF (5,200 people) starts finerenone during a hospital stay; CONFIRMATION starts it with empagliflozin. Both due November 2027.
842: worsening heart failure events with finerenone, vs 1,024 with placebo.
A heart-muscle booster returnsPossible
Cytokinetics' COMET-HF (1,800 people) tests omecamtiv mecarbil in severely reduced pumping; due September 2027.
-
3 years
by late 2029
Blocking aldosterone productionPossible
Boehringer's vicadrostat plus empagliflozin trials (10,900 people) report from May 2028.
A monthly weight-loss shot for HFpEFPossible 9.9% death or worsening HF (tirzepatide)
Amgen's MARITIME-HF (5,056 people) tests maridebart cafraglutide in HFpEF and HFmrEF with obesity; due June 2028.
9.9%: had cardiovascular death or worsening heart failure with tirzepatide, vs 15.3%.
-
5 years
by late 2031
Preventing heart failurePossible
AstraZeneca's Prevent-HF (11,300 people, due December 2029) tests baxdrostat with dapagliflozin in people at risk.
Pills and new weight drugs for outcomesPossible
Elevate-HF (elecoglipron pill, due September 2029) and HF-POLARIS (due July 2029) test whether newer obesity drugs reduce heart failure events.
Clearing amyloid from the heartLong shot
Novo Nordisk's CLEOPATTRA (1,280 people, due June 2029) tests coramitug, an antibody that removes ATTR amyloid deposits.
The research paths
Aldosterone and MRA drugs
842 worsening HF eventsDetails and 8 trialsHide
Finerenone and new drugs that stop the body making aldosterone (vicadrostat, baxdrostat, balcinrenone), often paired with SGLT2 inhibitors.
WatchREDEFINE-HF; BalanceD-HF; vicadrostat trials.
- Finerenone started in hospital (REDEFINE-HF)Colorado Prevention Center · 5,200 people · enrolling Nov 2027
- Finerenone plus empagliflozin together (CONFIRMATION)Colorado Prevention Center · 1,500 people · enrolling Nov 2027
- Finerenone when spironolactone is not tolerated (FINALITY-HF)Colorado Prevention Center · 2,600 people · enrolling Aug 2026
- Balcinrenone plus dapagliflozin (BalanceD-HF)AstraZeneca · 3,850 people · enrolling Apr 2027
- Vicadrostat plus empagliflozinBoehringer Ingelheim · 6,712 people · enrolling May 2028
- Vicadrostat plus empagliflozin, second trialBoehringer Ingelheim · 4,200 people · enrolling Feb 2029
- Baxdrostat plus dapagliflozin to prevent heart failure (Prevent-HF)AstraZeneca · 11,300 people · enrolling Dec 2029
- Spironolactone in HFpEF (SPIRRIT)Uppsala University · 2,000 people · enrolling Dec 2026
Obesity drugs for the heart
9.9% death or worsening HFDetails and 3 trialsHide
GLP-1-based drugs and new long-acting or oral versions tested for heart failure outcomes, mostly in HFpEF.
WatchMARITIME-HF; HF-POLARIS.
Inflammation and heart muscle
Details and 3 trialsHide
IL-6 blockers, heart-muscle activators and amyloid-clearing antibodies.
WatchATHENA; COMET-HF; CLEOPATTRA.
- Ziltivekimab, an anti-inflammatory antibody (ATHENA)Novo Nordisk · 673 people · fully enrolled Oct 2026
- Omecamtiv mecarbil, severely reduced pumping (COMET-HF)Cytokinetics · 1,800 people · enrolling Sep 2027
- Coramitug for ATTR cardiomyopathy (CLEOPATTRA)Novo Nordisk · 1,280 people · enrolling Jun 2029
Devices and valves
52.4% event-free at 3 yearsDetailsHide
Catheter valve repair, shunts and other procedures for people still struggling on medicines.
WatchLonger follow-up of tricuspid repair.
Borrowed from other conditions
From Diabetes and obesity
Tirzepatide and semaglutide
Approved for other uses
Weight-loss drugs that improved symptoms and outcomes in obesity-related HFpEF.
From Resistant high blood pressure
Baxdrostat and vicadrostat
Phase 3
Aldosterone synthase inhibitors first developed to lower hard-to-treat blood pressure.
From Kidney disease and heart attack prevention
Ziltivekimab
Phase 3
An IL-6 antibody also tested to lower heart risk in chronic kidney disease.
Open to join now
-
Hospitalized heart failure
Finerenone started in hospital
Locations and eligibility → -
HFpEF or HFmrEF with obesity
Maridebart cafraglutide
Locations and eligibility → -
Heart failure
Vicadrostat plus empagliflozin
Locations and eligibility → -
Severely reduced ejection fraction
Omecamtiv mecarbil
Locations and eligibility → -
Heart failure with obesity
NNC0487-0111
Locations and eligibility →
See every recruiting Heart failure trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
What just happened
Ziltivekimab outcomes trial HERMES listed as terminated
ClinicalTrials.gov record.
Tricuspid valve repair cuts death or hospitalization
TRIC-I-HF, NEJM.
Digitoxin lowers death or hospitalization in HFrEF
DIGIT-HF, NEJM.
Standard treatment today
- Reduced ejection fraction (40% or less)ARNI (sacubitril-valsartan), beta-blocker, MRA and SGLT2 inhibitor; devices (ICD, CRT) for some.
- Mildly reduced or preserved (over 40%)SGLT2 inhibitor, finerenone or another MRA, diuretics; semaglutide or tirzepatide with obesity.
- Hospital stay for worsening heart failureIV diuretics, then starting or restarting guideline drugs before going home.
- Advanced heart failureLVAD pumps or heart transplant for selected patients.
- Valve problemsCatheter repair of leaky mitral or tricuspid valves for selected patients.
How to read this page, and sourcesHow to read this page, and sources
- Treatment depends on ejection fraction (how strongly the heart pumps); ask what yours is.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See Heart failure trials recruiting now →